Literature DB >> 29748936

Semi-quantitative dopamine transporter standardized uptake value in comparison with conventional specific binding ratio in [123I] FP-CIT single-photon emission computed tomography (DaTscan).

Yuichi Wakabayashi1, Ryuichi Takahashi2, Tomonori Kanda3, Feibi Zeng3, Munenobu Nogami3, Kazunari Ishii4, Takamichi Murakami3.   

Abstract

PURPOSE: We developed a new analytical method to quantify the dopamine transporter (DAT) radiation dose in the striatum on [123I] FP-CIT single-photon emission computed tomography (SPECT). This method is based on the dopamine transporter standardized uptake value (DaTSUV). The purpose of this study was to compare DaTSUV with the classical specific binding ratio (SBR) in the discrimination of dopaminergic neurodegenerative diseases (dNDD) from non-dNDD.
METHOD: Seventy-seven consecutive patients who underwent DaTscan were included. Patients were divided into a dNDD group (n = 44; 24 men, 20 women; median age 73 years) and a non-dNDD group (n = 33; 14 men, 19 women; median age 75 years) based on their clinical diagnoses. The relationship between each method was evaluated by Pearson's correlation coefficient. Differences in SBR and DaTSUV in each group were evaluated by t test. Pairwise comparison of receiver operating characteristic (ROC) curve analysis was performed to compare the discriminating abilities of each method according to the standard error of the area under the curve (AUC). A value of p < 0.05 was considered statistically significant. RESULT: There was a significant strong correlation between DaTSUV and SBR (r = 0.910 [95% CI = 0.862-0.942], p < 0.001). The dNDD group showed significantly lower SBR (3.48 [1.25-7.91] vs 6.58 [3.81-11.1], p < 0.001) and DaTSUV (4.91 [1.59-13.6] vs 8.61 [2.29-15.6], p < 0.001) than the non-dNDD group. The discriminating ability of SBR (AUC = 0.918) was significantly higher than that of DaTSUV (AUC = 0.838, p = 0.0176).
CONCLUSION: DaTSUV has a good correlation with SBR, but it could not exceed SBR for discriminating dNDD from non-dNDD.

Entities:  

Keywords:  DaTscan; Dopaminergic neurodegenerative diseases; SBR; SUV; [123I] FP-CIT SPECT

Mesh:

Substances:

Year:  2018        PMID: 29748936     DOI: 10.1007/s10072-018-3437-8

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  39 in total

1.  Comparison of diagnostic utility of semi-quantitative analysis for DAT-SPECT for distinguishing DLB from AD.

Authors:  Soichiro Shimizu; Nayuta Namioka; Daisuke Hirose; Hidekazu Kanetaka; Kentaro Hirao; Hirokuni Hatanaka; Naoto Takenoshita; Yoshitsugu Kaneko; Yusuke Ogawa; Akito Tsugawa; Takahiko Umahara; Hirofumi Sakurai; Haruo Hanyu
Journal:  J Neurol Sci       Date:  2017-03-27       Impact factor: 3.181

Review 2.  An evidence-based review of quantitative SPECT imaging and potential clinical applications.

Authors:  Dale L Bailey; Kathy P Willowson
Journal:  J Nucl Med       Date:  2013-01       Impact factor: 10.057

3.  Measurement of absolute myocardial blood flow in humans using dynamic cardiac SPECT and 99mTc-tetrofosmin: Method and validation.

Authors:  Uttam Shrestha; Maria Sciammarella; Fares Alhassen; Yerem Yeghiazarians; Justin Ellin; Emily Verdin; Andrew Boyle; Youngho Seo; Elias H Botvinick; Grant T Gullberg
Journal:  J Nucl Cardiol       Date:  2015-12-29       Impact factor: 5.952

4.  Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.

Authors:  T Brücke; S Asenbaum; W Pirker; S Djamshidian; S Wenger; C Wöber; C Müller; I Podreka
Journal:  J Neural Transm Suppl       Date:  1997

5.  [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease.

Authors:  Willibald Gerschlager; Gerhard Bencsits; Walter Pirker; Bastiaan R Bloem; Susanne Asenbaum; Daniella Prayer; Jan C M Zijlmans; Martha Hoffmann; Thomas Brücke
Journal:  Mov Disord       Date:  2002-05       Impact factor: 10.338

6.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

Review 7.  Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.

Authors:  Ian G McKeith; Bradley F Boeve; Dennis W Dickson; Glenda Halliday; John-Paul Taylor; Daniel Weintraub; Dag Aarsland; James Galvin; Johannes Attems; Clive G Ballard; Ashley Bayston; Thomas G Beach; Frédéric Blanc; Nicolaas Bohnen; Laura Bonanni; Jose Bras; Patrik Brundin; David Burn; Alice Chen-Plotkin; John E Duda; Omar El-Agnaf; Howard Feldman; Tanis J Ferman; Dominic Ffytche; Hiroshige Fujishiro; Douglas Galasko; Jennifer G Goldman; Stephen N Gomperts; Neill R Graff-Radford; Lawrence S Honig; Alex Iranzo; Kejal Kantarci; Daniel Kaufer; Walter Kukull; Virginia M Y Lee; James B Leverenz; Simon Lewis; Carol Lippa; Angela Lunde; Mario Masellis; Eliezer Masliah; Pamela McLean; Brit Mollenhauer; Thomas J Montine; Emilio Moreno; Etsuro Mori; Melissa Murray; John T O'Brien; Sotoshi Orimo; Ronald B Postuma; Shankar Ramaswamy; Owen A Ross; David P Salmon; Andrew Singleton; Angela Taylor; Alan Thomas; Pietro Tiraboschi; Jon B Toledo; John Q Trojanowski; Debby Tsuang; Zuzana Walker; Masahito Yamada; Kenji Kosaka
Journal:  Neurology       Date:  2017-06-07       Impact factor: 9.910

8.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Authors:  Günter U Höglinger; Gesine Respondek; Maria Stamelou; Carolin Kurz; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Christer Nilsson; Jennifer L Whitwell; Thomas Arzberger; Elisabet Englund; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Yaroslau Compta; Jean-Christophe Corvol; Carlo Colosimo; Dennis W Dickson; Richard Dodel; Leslie Ferguson; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw R Morris; Peter Nestor; Wolfgang H Oertel; Werner Poewe; Gil Rabinovici; James B Rowe; Gerard D Schellenberg; Klaus Seppi; Thilo van Eimeren; Gregor K Wenning; Adam L Boxer; Lawrence I Golbe; Irene Litvan
Journal:  Mov Disord       Date:  2017-05-03       Impact factor: 10.338

Review 9.  Neuroimaging in Parkinson disease: from research setting to clinical practice.

Authors:  Marios Politis
Journal:  Nat Rev Neurol       Date:  2014-11-11       Impact factor: 42.937

10.  Quantification of 99mTc-DPD concentration in the lumbar spine with SPECT/CT.

Authors:  Michal Cachovan; Alexander Hans Vija; Joachim Hornegger; Torsten Kuwert
Journal:  EJNMMI Res       Date:  2013-06-05       Impact factor: 3.138

View more
  1 in total

1.  A new quantitative index in the diagnosis of Parkinson syndrome by dopamine transporter single-photon emission computed tomography.

Authors:  Ryota Bando; Hideki Otsuka; Tamaki Otani; Noritake Matsuda; Shota Azane; Yamato Kunikane; Yoichi Otomi; Wataru Sako; Yuishin Izumi; Masafumi Harada
Journal:  Ann Nucl Med       Date:  2021-02-25       Impact factor: 2.668

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.